Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.

CONCLUSIONS: Use of HIPEC for ovarian cancer increased in the US after publication of a phase III clinical trial in a high-impact journal, though the absolute number of cases remains modest. Incorporation of HIPEC was associated with increased cost, hospital length of stay, ICU admission, and hospital-acquired complication rates. Further studies are needed in order to evaluate long-term outcomes, including morbidity and survival.
PMID: 32977989 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - September 21, 2020 Category: Cancer & Oncology Authors: Charo LM, Jou J, Binder P, Hohmann SF, Saenz C, McHale M, Eskander RN, Plaxe S Tags: Gynecol Oncol Source Type: research